ArticleFrontiers in cellular and infection microbiology2022
Carbapenem-resistant hypermucoviscous
Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Antimicrobial resistance in hypermucoviscous and non-hypermucoviscousEmerging microbes & infections · 2025Pooled it
- Genomic characterization ofMicrobiology spectrum · 2026Article
- HypervirulentMicrobiology spectrum · 2026Article
- Antibiotic resistance profiles and co-occurrence of ESBL and AmpC β-lactamase genes in ESBL-producing Gram-negative bacteria of clinical origin.BMC microbiology · 2026Article
- Prevalence and Multidrug Resistance of WHO-Priority Bacterial Pathogens in a Romanian Intensive Care Unit.Journal of clinical medicine · 2026Article
- Intrinsic Acidity of N-Acetylcysteine Mediates Enhanced Inhibition ofMicroorganisms · 2026Article
- Virulence and Genomic Profiles of Klebsiella pneumoniae Isolated from Pediatric Patients in Henan, China (2021-2023).Current medical science · 2025Article
- Article
- Prevalence and molecular characterisation of multi-drug resistant ST11 hypervirulent Klebsiella pneumoniae in a teaching hospital.BMC microbiology · 2025Article
- Prevalence, Risk Factors, and Clinical Outcomes of HypervirulentIndian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025Article
- Bacteriophage-derived depolymerase: a review on prospective antibacterial agents to combat Klebsiella pneumoniae.Archives of virology · 2025Review
- Synergistic combination of ceftazidime and avibactam with Aztreonam against MDR Klebsiella pneumoniae in ICU patients.Scientific reports · 2025Article
- Therapeutic efficacy of different sulperazon dosing regimens in carbapenem-resistant Klebsiella pneumoniae: a retrospective analysis of 209 cases.American journal of translational research · 2025Article
- Hypervirulent Carbapenem-resistantInfection and drug resistance · 2025Review
- Retrospective Case-Control Study of Risk Factors for Carbapenem-ResistantPathogens (Basel, Switzerland) · 2024Article
- Prevalence of Infections and Antimicrobial Resistance of ESKAPE Group Bacteria Isolated from Patients Admitted to the Intensive Care Unit of a County Emergency Hospital in Romania.Antibiotics (Basel, Switzerland) · 2024Article
- TiOMicroorganisms · 2024Review
- Comprehensive study reveals phenotypic heterogeneity in Klebsiella pneumoniae species complex isolates.Scientific reports · 2024Article
- The Global and Regional Prevalence of Hospital-Acquired Carbapenem-ResistantOpen forum infectious diseases · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypervirulent and multidrug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.